



164287  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Figdor et al.

Serial No.: 09/214,836

Filed: October 4, 1999

For: MELANOMA ASSOCIATED  
PEPTIDE ANALOGUES AND VACCINES  
AGAINST MELANOMA

Confirmation No.: 8137

Examiner: S. Rawlings, Ph.D.

Group Art Unit: 1642

Attorney Docket No.: 2578-4230US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

March 25, 2004  
Date

  
Signature

Betty Vowles  
Name (Type/Print)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in

03/29/2004 SSANDARA 00000007 09214836

01 FC:1806

180.00 OP

37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

<u>U.S. Patent Documents</u>		
<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
US- 2002/0076392 A1	06-20-2002	Hoo
US- 4,485,086	11/27/1984	Wong
US- 5,376,531	12/27/1994	Anderson et al.
US- 5,783,567	07-21-1998	Hedley et al.
US- 5,874,560	02-23-1999	Kawakami et al.
US- 5,891,432	04-06-1999	Hoo
US- 5,965,381	10-12-1999	van der Bruggen et al.
US- 5,965,535	10-12-1999	Chaux et al.
US- 5,994,523	11-30-1999	Kawakami et al.
US- 6,245,525 B1	06-12-2001	Martelange et al.
US- 6,270,778 B1	08-07-2001	Kawakami et al.
US- 6,291,430 B1	09-18-2001	Chaux et al.
US- 6,303,756 B1	10-16-2001	Martelange et al.
US- 6,369,211 B1	04-09-2002	Chaux et al.
US- 6,407,063 B1	06-18-2002	Luiten et al.
US- 6,426,217 B1	07-30-2002	Chaux et al.
US- 6,500,919 B1	12/31/2002	Adema et al.
US-4,405,712	09-20-1983	Vande Woude et al.
US-4,497,796	02-05-1985	Salser et al.
US-4,727,028	02-23-1988	Santerre et al.
US-4,740,463	04-26-1988	Weinberg et al.
US-5,190,931	03-02-1993	Inouye
US-5,208,149	05-04-1993	Inouye
US-5,262,177	11-16-1993	Brown et al.

**Serial No.: 09/214,836**

US-5,342,774	08-30-1994	Boon et al.
US-5,518,913	05-21-1996	Massie et al.
US-5,837,511	11-17-1998	Falck-Pedersen et al.
US-5,994,106	11-30-1999	Kovesdi et al.
US-5,994,128	11-30-1999	Fallaux et al.
US-6,033,908	03-07-2000	Bout et al.
US-6,040,174	03-21-2000	Imler et al.
US-6,537,560	03-25-2003	Kawakami et al.
US-2003/0144482 A1	07-31-2003	Kawakami et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
WO 00/20445	04-13-2000	Chaux
WO 00/20581	04-13-2000	Ludwig Institute
WO 98/31398	07-23-1998	Pangaea Pharmaceuticals, Inc.
WO 99/06544	02-11-1999	The Immune Response Corp.
WO 99/14326	03-25-1999	Ludwig Institute
WO 99/45098	09-10-1999	van der Bruggen
WO 99/53061	10-21-1999	Ludwig Institute
EP-0174608	03-19-1986	Leavitt
WO 92/21767	12-10-1992	Bristol-Myers
WO 93/14189	04-22-1993	Ludwig Institute
WO 94/23067	10-13-1994	Abbott Labs
WO 94/28152	12-08-1994	Transgene S.A.
WO 95/02697	01-26-1995	Rhonepoulenc Rorer S.A.
WO 95/22561	08-24-1995	Univ. of Virginia
WO 95/29193	11-02-1995	The Government of the United States of America
JP9027482A2	01-28-1997	Speedfam Co.

Other Documents

ADEMA et al., Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA, The American Journal of Pathology, 1993, Vol. 143, No. 6, pp. 1579-1585.

ADEMA, et al., Molecular Characterization of the Melanocyte Lineage-specific Antigen gp100, J. Biol. Chem., 1994, Vol. 269, No. 31, pp. 20126-20133

BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Biol., 1990, 11:2129-2138.

CURTI, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.

European Search Report, EP 94 20 0337, dated 27 July 1994.

LEE et al., Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression, Journal of Immunology, 1999, pp. 6292-6300, Vol.163.

GILLIES et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, no. 1, pp. 47-54.

JAIN, Sci. Am. 271:58-65, 1994.

KAWAKAMI, et al., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with *in vivo* tumor rejection, Proc. Natl. Acad. Sci., 1994, Vol. 91, pp. 6458-6462.

KWON et al., A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a cyntenic region on human chromosome 12, Proceedings of the National Academy of Sciences of USA, 88:20:9228-9232, October 15, 1991, Washington D.C., USA.

LAZAR et al., Transforming Growth Factor  $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell Biol., 1988, Vol. 8, pp. 1247-1252.

MPSRCH Search Report Seg ID No. 22, p. 1-3 (2001).

MPSRCH Search Report, for Seg ID No. 21, p. 1-2 (2001).

OSBAND et al., Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, 1990, 11(6):193-195.

MARCHAND et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 1995 63, 883-885, Wiley-Liss, Inc.

ROSENBERG et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nature Medicine, March 1998, Vol 4, No. 3, pp. 321-327

ROSENBERG, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunology Today, Vol. 18, No. 4, April 1997, pp. 175-182.

SLINGLUFF et al., Abstract, Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, The Journal of Immunology, April 1, 1993, pp. 2955-2963, vol. 150, No. 7, The American Association of Immunologists, USA.

TAO et al., Studies of Aglycosylated Chimeric Mouse-Human IgG, J. Immunol., 1989, Vol. 143, No. 8, pp. 2595-2601.

VOGEL et al., Human 95kD melanocyte-specific secreted glycoprotein mRNA, 3' end EMBL Database, Accession No. M32295, November 26, 1990.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor(s):

Attorney Docket No.: 2578-3938.1US

Serial No.: 10/136,145

Filing Date: 5/1/2002


Title: MELANOMA ASSOCIATED ANTIGENIC POLYPEPTIDE,  
EPITOPES THEREOF AND VACCINES AGAINST  
MELANOMA

Serial No.: 09/214,836

This Supplemental Information Disclosure Statement is filed after the mailing date of the first Office Action on the merits subsequent to the filing of an RCE in the above-identified application.

The fee pursuant to 37 C.F.R. § 1.17(p) is enclosed.

Respectfully submitted,




Bretton L. Crockett  
Registration No. 44,632  
Attorney for Applicant(s)  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: March 25, 2004  
BLC/bv

Enclosures: Form PTO-1449 or PTO/SB/08  
Cited Documents  
Check in the amount of \$180.00

Document in ProLaw



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

**Complete if Known**

Application Number	09/214,836
Filing Date	October 4, 1999
First Named Inventor	Figdor et al.
Group Art Unit	1642
Examiner Name	S. Rawlings, Ph.D.
Attorney Docket Number	2578-4230US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 2002/0076392 A1	06-20-2002	Hoo	
		US- 4,485,086	11/27/1984	Wong	
		US- 5,376,531	12/27/1994	Anderson et al.	
		US- 5,783,567	07-21-1998	Hedley et al.	
		US- 5,874,560	02-23-1999	Kawakami et al.	
		US- 5,891,432	04-06-1999	Hoo	
		US- 5,965,381	10-12-1999	van der Bruggen et al.	
		US- 5,965,535	10-12-1999	Chaux et al.	
		US- 5,994,523	11-30-1999	Kawakami et al.	
		US- 6,245,525 B1	06-12-2001	Martelange et al.	
		US- 6,270,778 B1	08-07-2001	Kawakami et al.	
		US- 6,291,430 B1	09-18-2001	Chaux et al.	
		US- 6,303,756 B1	10-16-2001	Martelange et al.	
		US- 6,369,211 B1	04-09-2002	Chaux et al.	
		US- 6,407,063 B1	06-18-2002	Luiten et al.	
		US- 6,426,217 B1	07-30-2002	Chaux et al.	
		US- 6,500,919 B1	12/31/2002	Adema et al.	

**FOREIGN PATENT DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 00/20445	04-13-2000	Chaux		
		WO 00/20581	04-13-2000	Ludwig Institute		
		WO 98/31398	07-23-1998	Pangaea Pharmaceuticals, Inc.		
		WO 99/06544	02-11-1999	The Immune Response Corp.		
		WO 99/14326	03-25-1999	Ludwig Institute		
		WO 99/45098	09-10-1999	van der Bruggen		
		WO 99/53061	10-21-1999	Ludwig Institute		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	09/214,836
Filing Date	October 4, 1999
First Named Inventor	Figdor et al.
Group Art Unit	1642
Examiner Name	S. Rawlings, Ph.D.
Attorney Docket Number	2578-4230US

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-4,405,712	09-20-1983	Vande Woude et al.	
		US-4,497,796	02-05-1985	Salser et al.	
		US-4,727,028	02-23-1988	Santerre et al.	
		US-4,740,463	04-26-1988	Weinberg et al.	
		US-5,190,931	03-02-1993	Inouye	
		US-5,208,149	05-04-1993	Inouye	
		US-5,262,177	11-16-1993	Brown et al.	
		US-5,342,774	08-30-1994	Boon et al.	
		US-5,518,913	05-21-1996	Massie et al.	
		US-5,837,511	11-17-1998	Falck-Pedersen et al.	
		US-5,994,106	11-30-1999	Kovesdi et al.	
		US-5,994,128	11-30-1999	Fallaux et al.	
		US-6,033,908	03-07-2000	Bout et al.	
		US-6,040,174	03-21-2000	Imler et al.	
		US-6,537,560	03-25-2003	Kawakami et al.	
		US-2003/0144482 A1	07-31-2003	Kawakami et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		EP-0174608	03-19-1986	Leavitt		
		WO 92/21767	12-10-1992	Bristol-Myers		
		WO 93/14189	04-22-1993	Ludwig Institute		
		WO 94/23067	10-13-1994	Abbott Labs		
		WO 94/28152	12-08-1994	Transgene S.A.		
		WO 95/02697	01-26-1995	Rhonepoulenc Rorer S.A.		
		WO 95/22561	08-24-1995	Univ. of Virginia		
		WO 95/29193	11-02-1995	The Government of the United States of America		
		JP9027482A2	01-28-1997	Speedfam Co.		


Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.





PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

**Complete if Known**

Application Number	09/214,836
Filing Date	October 4, 1999
First Named Inventor	Figdor et al.
Group Art Unit	1642
Examiner Name	S. Rawlings, Ph.D.
Attorney Docket Number	2578-4230US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ADEMA et al., Melanocyte lineage-specific antigens recognized by monoclonal antibodies NK1-beteb, HMB-50, and HMB-45 are encoded by a single cDNA, The American Journal of Pathology, 1993, Vol. 143, No. 6, pp. 1579-1585.	
		ADEMA, et al., Molecular Characterization of the Melanocyte Lineage-specific Antigen gp100, J. Biol. Chem., 1994, Vol. 269, No. 31, pp. 20126-20133	
		BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, J. Cell Biol., 1990, 11:2129-2138.	
		CURTI, Crit. Rev. Oncol/Hematol. 14:29-39, 1993.	
		European Search Report, EP 94 20 0337, dated 27 July 1994.	
		GILLIES et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Human Antibody. Hybridomas, 1990, vol. 1, no. 1, pp. 47-54.	
		JAIN, Sci. Am. 271:58-65, 1994.	
		KAWAKAMI, et al., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with <i>in vivo</i> tumor rejection, Proc. Natl. Acad. Sci., 1994, Vol. 91, pp. 6458-6462.	
		KWON et al., A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a cyntenic region on human chromosome 12, Proceedings of the National Academy of Sciences of USA, 88:20:9228-9232, October 15, 1991, Washington D.C., USA.	
		LAZAR et al., Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell Biol., 1988, Vol. 8, pp. 1247-1252.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	09/214,836
Filing Date	October 4, 1999
First Named Inventor	Figdor et al.
Group Art Unit	1642
Examiner Name	S. Rawlings, Ph.D.
Attorney Docket Number	2578-4230US

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MPSRCH Search Report Seg ID No. 22, p. 1-3 (2001).	
		MPSRCH Search Report, for Seg ID No. 21, p. 1-2 (2001).	
		OSBAND et al., Problems in the investigational study and clinical use of cancer immunotherapy, Immunology Today, 1990, 11(6):193-195.	
		MARCHAND et al., Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3, Int. J. Cancer, 1995 63, 883-885, Wiley-Liss, Inc.	
		ROSENBERG et al., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nature Medicine, March 1998, Vol 4, No. 3, pp. 321-327	
		ROSENBERG, Cancer vaccines based on the identification of genes encoding cancer regression antigens, Immunology Today, Vol. 18, No. 4, April 1997, pp. 175-182.	
		SLINGLUFF et al., Abstract, Recognition of Human Melanoma Cells by HLA-A2.1-Restricted Cytotoxic T Lymphocytes Is Mediated by at Least Six Shared Peptide Epitopes, The Journal of Immunology, April 1, 1993, pp. 2955-2963, vol. 150, No. 7, The American Association of Immunologists, USA.	
		TAO et al., Studies of Aglycosylated Chimeric Mouse-Human IgG, J. Immunol., 1989, Vol. 143, No. 8, pp. 2595-2601.	
		VOGEL et al., Human 95kD melanocyte-specific secreted glycoprotein mRNA, 3' end EMBL Database, Accession No. M32295, November 26, 1990.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.